第二个线粒体衍生半胱天冬氨酸蛋白酶激活剂模拟物与乳腺癌治疗  

Smac mimics and treatment of breast cancer

作　　者：赵玉立 张艺馨 王森 郭慧敏 封丽 ZHAO Yuli;ZHANG Yixin;WANG Sen;GUO Huimin;FENG Li(Graduate School of Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Medical Ultrasound,The First Affiliated Hospital of Shandong First Medical University(Shandong Provincial Qian Foshan Hospital),Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging,Jinan 250014,China)

机构地区：[1]山东第一医科大学(山东省医学科学院)研究生部,山东济南250117 [2]山东第一医科大学第一附属医院(山东省千佛山医院)超声医学科,山东省医药卫生腹部医学影像学重点实验室,山东济南250014

出　　处：《山东第一医科大学（山东省医学科学院）学报》2023年第9期702-706,共5页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

摘　　要：第二个线粒体衍生半胱天冬氨酸蛋白酶激活剂(second mitochondria‐derived activator of caspase,Smac)蛋白是一类存在于线粒体中的凋亡抑制蛋白(inhibitor of apoptosis protein,IAP)拮抗剂,在肿瘤细胞凋亡过程中从线粒体释放,与IAP结合抑制其功能。目前Smac模拟物已经成为癌症中一类很有前途的靶向疗法,正在进行临床测试。乳腺癌作为全球女性最常见的癌症,其治疗受到广泛关注。本文针对Smac模拟物在乳腺癌治疗中的相关研究进展作一综述。Second mitochondria-derived activator of caspase(Smac)protein is a natural antagonist of inhibitor of apoptosis protein(IAP)present in mitochondria.Smac protein is released from mitochondria during tumor cell apoptosis and binds to IAP to inhibit its function.Smac mimetics have now emerged as a promising class of targeted therapies in cancer and are being tested in the clinic.Breast cancer is the most common cancer among women in the world,and its treatment is widely concerned.In this review,the research progress related to Smac mimics in breast cancer treatment is summarized.

关 键 词：Smac模拟物 促凋亡 乳腺癌 治疗 

分 类 号：R737.9[医药卫生—肿瘤]